Merck KGaA (OTCMKTS:MKKGY) Releases Earnings Results, Misses Estimates By $0.26 EPS

Merck KGaA (OTCMKTS:MKKGY) posted its quarterly earnings results on Thursday. The company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.26), Zacks reports. Merck KGaA had a return on equity of 8.10% and a net margin of 11.20%.

Merck KGaA Trading Down 3.1%

OTCMKTS:MKKGY traded down $1.05 during trading hours on Thursday, hitting $32.79. The company had a trading volume of 61,679 shares, compared to its average volume of 94,316. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.69 and a quick ratio of 1.09. The stock has a 50-day moving average price of $31.71 and a 200 day moving average price of $30.07. The company has a market capitalization of $21.19 billion, a PE ratio of 16.90, a price-to-earnings-growth ratio of 2.92 and a beta of 0.92. Merck KGaA has a 52 week low of $23.73 and a 52 week high of $34.19.

Analyst Ratings Changes

MKKGY has been the subject of a number of recent research reports. Zacks Research raised Merck KGaA from a “strong sell” rating to a “hold” rating in a research note on Tuesday. UBS Group lowered Merck KGaA from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 20th. Six analysts have rated the stock with a Hold rating. Based on data from MarketBeat.com, Merck KGaA has a consensus rating of “Hold”.

About Merck KGaA

Merck KGaA is a German science and technology company headquartered in Darmstadt. Founded in 1668, it traces its origins to a pharmacy established by the Merck family and has grown into a global business serving customers in healthcare, research and industry. It is separate from the U.S.-based Merck & Co. The company operates through three main businesses. Its Healthcare division develops and markets prescription medicines, including treatments in areas such as oncology, neurology and fertility.